Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.

Kostas DelaunayJulien EdelineYan RollandNicolas LepareurSophie LaffontXavier PalardChristelle BouvrySamuel Le SourdMarc PrachtValérie ArdissonNicolas NoiretÉric BellissantEtienne Garin

Published in: European journal of nuclear medicine and molecular imaging (2019)

188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.

Keyphrases

clinical trial
pet imaging
liver metastases
open label
phase ii
study protocol
double blind